类风湿性关节炎
免疫学
滑膜炎
医学
关节炎
自身免疫性疾病
炎症
免疫
免疫系统
细胞毒性
疾病
肿瘤坏死因子α
滑膜
体外
癌症研究
髓系细胞
细胞毒性T细胞
巨噬细胞
生物
实验病理学
炎性关节炎
分泌物
移植排斥反应
免疫病理学
T细胞
受体
自身免疫
祖细胞
髓样
作者
Chamutal Gur,Lior Ravkaie,Reut Sharet-Eshed,Rotem Shalita,Roberto Avellino,Einat Rauchbach,Ken Xie,Eyal David,Gal Yagel,Mor Zada,Maya Ben Yehuda,Kfir Mazuz,Michelle von Locquenghien,Hagit Peleg,Yaakov Naparstek,Karine Atlan,Shlomit Kfir‐Erenfeld,Yuri Kuznetsov,Reut Tzemach,Merav Lidar
出处
期刊:
[Cold Spring Harbor Laboratory]
日期:2026-07-12
被引量:1
标识
DOI:10.64898/2026.07.09.737520
摘要
Abstract Despite major therapeutic advances, a substantial fraction of patients with autoimmune disease remains refractory to treatment. While B cell-targeted CAR-T therapies have shown considerable efficacy, the central contribution of pathogenic T cells to rheumatoid arthritis (RA) suggests that complementary T cell-directed strategies may enable deeper disease control. Using single-cell multi-omics of human RA and experimental models, PDCD1 was identified as a selective marker of synovial disease-associated T cells. We developed PD-1-directed CAR-T cells that potently eliminate these cells in vitro and in vivo , leading to marked attenuation of synovitis in RA models. To limit off-target activity, we engineered NR4A2-driven CAR-responsive biosensors to restrict CAR activity to inflamed synovium. To couple anti-PD-1 CAR-mediated cytotoxicity with microenvironmental modulation, we further engineered these CAR-T cells to secrete soluble TNF receptor II (sTNFRii), counteracting baseline inflammation and CAR-induced IFN response and promoting a tissue-reparative myeloid state. PD-1-targeted CAR-T therapy thus represents a promising, specific, and safe strategy for autoimmune diseases involving disease-associated T cells.
科研通智能强力驱动
Strongly Powered by AbleSci AI